Table 1 TTS patients’ characteristics: Entire cohort and subdivision according to previous diagnosis of A/Ca. Statistical comparisons are between A/Ca and no A/Ca subgroups
From: Antecedent cancer in Takotsubo syndrome predicts both cardiovascular and long-term mortality
|  | Entire group (n = 346) | A/Ca (n = 58) | No A/Ca (n = 288) | p |
|---|---|---|---|---|
Duration of follow-up (years) | 4.1 (2.2–6.4) | 3.5 (1.2–5.8) | 4.4 (2.3–6.8) | 0.05 |
Age (years) | 69 ± 13 | 74 ± 10 | 68 ± 14 | 0.001 |
Male: (%) | 8.2 | 14.3 | 7.0 | NS |
Secondary TTS (%) | 34 | 47 | 31 | 0.02 |
Site (Apex; %) | 66.4 | 64.3 | 66.7 | NS |
Annual recurrence rate (%) | 2.1 | 1.8 | 2.2 | NS |
CVS risk factors | ||||
 Hypertension (%) | 56.0 | 54.7 | 57.2 | NS |
 Diabetes mellitus (%) | 18.2 | 17 | 18.4 | NS |
 Dyslipidemia (%) | 37.8 | 34.0 | 38.6 | NS |
 Current smoking (%) | 9.8 | 9.4 | 9.9 | NS |
Markers: size of acute attacks | ||||
 Minimal systolic BP (mmHg) | 97 ± 16 | 98 ± 15 | 96 ± 16 | NS |
 Acute LVEF (%) | 46 ± 12 | 44 ± 13 | 47 ± 12 | NS |
 Peak NT-proBNP (ng/L) | 4800 (2600–9000) | 5800 (3600–10,800) | 4600 (2500–8600) | 0.04 |
 Peak normetanephrine (pmol/L) | 980 (610–1400) | 960 (600–1460) | 980 (620–1410) | NS |
 Peak metanephrine (pmol/L) | 200 (200–270) | 210 (200–290) | 200 (200–270) | NS |
 Peak hs-CRP (mg/L) | 13 (6–44) | 23 (8–100) | 11 (6–38) | 0.01 |
 Peak troponin T (ng/L) | 400 (223–620) | 310 (187–564) | 400 (230–638) | NS |
In-hospital complications (%) | ||||
 Arrhythmias | 15.1 | 21.8 | 13.8 | NS |
 Shock | 7.4 | 12.7 | 6.4 | NS |
 Mortality | 3.2 | 8.9 | 2.1 | 0.02 |
 MACE | 20.3 | 30.9 | 18.2 | 0.04 |
Neoplasia (%) | ||||
 A/Ca (Prior/current) | 16.8 |  |  |  |
 Chemo/Immunotherapy |  | 34.6 |  |  |
 Subsequent neo malignancy |  | 6.9 |  |  |
Discharge CVS medications (%) | ||||
 ACEi/ARB | 78.4 | 88.2 | 76.5 | 0.07 |
 βBl | 42.6 | 31.3 | 44.7 | 0.09 |
 Statins | 50.5 | 45.1 | 51.5 | NS |
 Aspirin | 42.4 | 37.3 | 43.4 | NS |